论文部分内容阅读
目的探讨良性转归葡萄胎与恶性转变葡萄胎的差异表达蛋白质鉴定方法。方法对北京协和医院妇产科2005年9月至2006年12月的7例良性转归葡萄胎及11例恶性转变葡萄胎进行比较蛋白质组学研究,将提取的总蛋白利用双向凝胶电泳(2-DE)分离,对凝胶上的蛋白点进行比较分析,找出明显差异表达的蛋白点,采用基质辅助激光解吸电离飞行时间质谱(MALDI-TOF-MS),获得肽质量指纹图(PMF),在数据库中鉴定差异蛋白。结果(1)良性转归葡萄胎与恶性转变葡萄胎组织的双向凝胶电泳图谱上大多数蛋白点有很好的相关性,比较分析后共筛选出32个差异点。(2)对差异点进行肽质量指纹图分析,获得理想匹配的蛋白质17个,鉴定出一些细胞骨架蛋白,应激相关蛋白,凋亡相关蛋白,与信号转导、细胞增殖及分化相关的蛋白,其中11个可能与葡萄胎恶性转变相关。结论应用蛋白质组学技术成功鉴定了17个差异蛋白,其中11个可能与葡萄胎恶性转变相关,为进一步筛选用于评价葡萄胎预后的标志物奠定了基础。
Objective To investigate the differentially expressed protein identification method of benign outcome hydatidiform mole and malignant transformed hydatidiform mole. Methods The comparative proteomics study of 7 cases of benign outcome mole and 11 cases of malignant transitional mole from September 2005 to December 2006 in Peking Union Medical College Hospital was carried out. The extracted total protein was analyzed by two-dimensional gel electrophoresis 2-DE). The protein spots on the gel were compared to find out the differentially expressed protein spots. The mass-fingerprint of the peptide (PMF) was obtained by matrix-assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF- ) To identify differential proteins in the database. Results (1) There was a good correlation between benign outcome hydatidiform mole and malignant transformed hydatidiform mole in most of the spots on the two-dimensional gel electrophoresis pattern. Thirty-two differences were screened after comparative analysis. (2) Peptide fingerprinting analysis of the difference points, obtained 17 ideal matching proteins, identified a number of cytoskeletal proteins, stress related proteins, apoptosis related proteins, proteins involved in signal transduction, cell proliferation and differentiation , Of which 11 may be associated with malignant transformation of hydatidiform mole. Conclusion 17 differential proteins were successfully identified using proteomics techniques, of which 11 were related to the malignant transformation of hydatidiform mole, which laid the foundation for further screening of the markers for evaluating the prognosis of hydatidiform mole.